Posts Tagged ‘XELJANZ-tofacitinib-JAK’

  • Xeljanz (Tofacitinib) Rheumatoid Arthritis Commercial

    Xeljanz TV commercial puts new kick in RA ads? “Arms were made for hugging. Hands for holding. Feet, kicking. Better things than the joint pain and swelling of moderate to severe Rheumatoid Arthritis.” So begins the new Xeljanz direct to consumer TV ad. It’s rather different from the other Rheumatoid Arthritis drug commercials: It is […]

  • Efficacy of Xeljanz, Biologics, & DMARDs in Rheumatoid Disease

    Why should I feel like I failed? I’m not alone We probably agree it’s unfair to say, “patients fail treatments” instead of the reverse, but there is still disappointment. I was optimistic that my Rheumatoid disease would respond to Xeljanz, the new oral DMARD (disease modifying anti-rheumatic drug) from Pfizer. Unfortunately, my joint stiffness and […]

  • Xeljanz Rejected by European Medicines Agency

    EMA rejects Xeljanz authorization Late yesterday, the European Medicines Agency (EMA) rejected the Pfizer’s application to market Xeljanz (tofacitinib). The EMA application was refused because the Committee for Medicinal Products for Human Use (CHMP) “adopted a negative opinion” on approving Xeljanz, stating they were unconvinced its risks outweighed benefits. Last November, the FDA approved the […]

  • Rheumatoid Arthritis Drug Approved by US FDA: Pfizer’s Xeljanz Pill (Tofacitinib)

    For over two and a half years, we’ve followed Pfizer’s tofacitinib through clinical trials for FDA approval. Today, the U.S. FDA approved the new drug that will be called Xeljanz. Click here to read the full Pfizer press release for Xeljanz.   The first JAK for Rheumatoid Arthritis approved: “Xeljanz” The U.S. Food and Drug […]

  • Pfizer’s Rheumatoid Arthritis Pill Approved by Food and Drug Administration (FDA)

    Note: Click here to read more about Xeljanz, the first new oral medication for Rheumatoid Arthritis in 10 years, and a short list of questions and answers for patients. Sign up for regular blog updates by email to watch for more updates on this new treatment and others. Pfizer press release about Xeljanz NEW YORK–(BUSINESS […]

  • RA News: Pfizer Pill Beats Methotrexate, Alcohol Reduces RA Risk, Periodontal Disease High

    Pfizer oral JAK “superior” to methotrexate Pfizer released a statement about their two year study, ORAL Start, which puts their new oral JAK treatment for Rheumatoid Arthritis directly up against methotrexate.  The oral medication, currently called tofacitinib, is taken twice daily in either 5 or 10 mg doses. “Tofacitinib was found to be superior to […]

  • Mind-boggling! – Aftermath of Tofacitinib FDA Hearing Part 2

    After the FDA Arthritis Advisory Committee (AAC) hearing earlier this month for Pfizer’s new oral treatment for RA,  tofacitinib, we looked at the four distinct votes of the AAC and some of the ways the media responded to them. They ranged from serious to pitiful to laughable. But there’s more.     3 news bytes […]

  • Aftermath of the FDA Vote on Pfizer’s RA JAK Inhibitor, Tofacitinib

    After the tofacitinib FDA hearing, the votes are in, false perceptions persist, and patients still need relief. Some estimate that tofacitinib could be approved by the US FDA within a few months after mixed votes and mostly inaccurate press reports. It’s fitting this discussion takes place as begins its fourth year of reporting the […]

  • FDA Arthritis Advisory Committee Hearing for Pfizer’s RA JAK: Tofacitinb

    Advisory Committee hearing feed link My daughter Katie Beth and I are in Washington, DC for the final FDA Arthritis Advisory Committee (AAC) hearing about Pfizer’s JAK, tofacitinib. Early in the morning, Katie Beth and I will be en route to the meeting. The AAC meeting will be broadcast online with a live feed. We’ve […]

  • Attending an FDA Hearing for Pfizer’s JAK: Tofacitinib CP-690550

    Three years ago, one of the first friends I made through my blog was Angie. She got into a Pfizer clinical trial for tofacitinib (then called tasocitinib). She sent me some info about the trial, but my rheum doc wasn’t interested and I didn’t pursue it. The current excitement about Pfizer’s tofacitinib Tofacitinib is an […]

  • Pfizer’s JAK inhibitor Tofacitinib EMA Application Validated

    Pfizer JAK-3 press release “Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis: Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated […]

Would You Like Free Email Updates?
Stay in touch with RA Warrior.
We respect your privacy. Your email address will never be shared.